(Q46453144)

22 December 2017

title

VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate (English)

1 reference

22 December 2017

1 reference

Michel Farnier

1

1 reference

22 December 2017

Inna Perevozskaya

2

1 reference

22 December 2017

William V Taggart

3

1 reference

22 December 2017

Debra Kush

4

1 reference

22 December 2017

Yale B Mitchel

5

1 reference

22 December 2017

publication date

31 July 2008

1 reference

22 December 2017

Journal of Lipid Research

published in

1 reference

22 December 2017

volume

49

1 reference

22 December 2017

issue

12

1 reference

22 December 2017

page(s)

2641-2647

1 reference

22 December 2017

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

cites work

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

Insulin resistance and adiposity influence lipoprotein size and subclass concentrations. Results from the Insulin Resistance Atherosclerosis Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1194%2FJLR.P800034-JLR200

10.1194/JLR.P800034-JLR200

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017